Targets › IL5
3 programs from 2 companies in 19 trials: 9 Phase 4, 8 Phase 3, 2 Phase 2; Respiratory, Hematology, Immunology; next expected readout Mar 2027.
Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils. Also acts on activated and resting B-cells to induce immunoglobulin production, growth, and differentiation (By similarity). (UniProt, P05113)
Open in Phaseline: the race on IL5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Depemokimab Interleukin-5 inhibitor | IL5 | Phase 4 | Nasal Polyps; Eosinophilic Granulomatosis With Polyangiitis; Asthma; Hypereosinophilic Syndrome … | Mar 2027 |
| GSK | Mepolizumab Interleukin-5 inhibitor | IL5 | Phase 4 | Asthma; Chronic Rhinosinusitis with Nasal Polyps; Chronic Rhinosinusitis With Nasal Polyps; Nasal Polyps … | Jun 2028 |
| National Jewish Health | Reslizumab Interleukin-5 inhibitor | IL5 | Phase 2 | Asthma | – |
Asthma (6) Pulmonary Disease, Chronic Obstructive (3) Chronic Rhinosinusitis With Nasal Polyps (3) Nasal Polyps (2) Eosinophilic Granulomatosis With Polyangiitis (1) Hypereosinophilic Syndrome (1) Chronic Rhinosinusitis with Nasal Polyps (1) Chronic Sinusitis (1) Coronary Artery Disease (1)
antibody (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.